These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

716 related articles for article (PubMed ID: 26806808)

  • 1. Development and potential applications of CRISPR-Cas9 genome editing technology in sarcoma.
    Liu T; Shen JK; Li Z; Choy E; Hornicek FJ; Duan Z
    Cancer Lett; 2016 Apr; 373(1):109-118. PubMed ID: 26806808
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent Progress in CRISPR/Cas9 Technology.
    Mei Y; Wang Y; Chen H; Sun ZS; Ju XD
    J Genet Genomics; 2016 Feb; 43(2):63-75. PubMed ID: 26924689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The application of genome editing in studying hearing loss.
    Zou B; Mittal R; Grati M; Lu Z; Shu Y; Tao Y; Feng Y; Xie D; Kong W; Yang S; Chen ZY; Liu X
    Hear Res; 2015 Sep; 327():102-8. PubMed ID: 25987504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Application of CRISPR/Cas9 genome editing to the study and treatment of disease.
    Pellagatti A; Dolatshad H; Valletta S; Boultwood J
    Arch Toxicol; 2015 Jul; 89(7):1023-34. PubMed ID: 25827103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CRISPR/Cas9: molecular tool for gene therapy to target genome and epigenome in the treatment of lung cancer.
    Sachdeva M; Sachdeva N; Pal M; Gupta N; Khan IA; Majumdar M; Tiwari A
    Cancer Gene Ther; 2015 Nov; 22(11):509-17. PubMed ID: 26494554
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CRISPR-Cas9 systems: versatile cancer modelling platforms and promising therapeutic strategies.
    Wen WS; Yuan ZM; Ma SJ; Xu J; Yuan DT
    Int J Cancer; 2016 Mar; 138(6):1328-36. PubMed ID: 26044706
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CRISPR-mediated targeting of HER2 inhibits cell proliferation through a dominant negative mutation.
    Wang H; Sun W
    Cancer Lett; 2017 Jan; 385():137-143. PubMed ID: 27815036
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [CRISPR/Cas9-based genome editing systems and the analysis of targeted genome mutations in plants].
    Ma XL; Liu YG
    Yi Chuan; 2016 Feb; 38(2):118-25. PubMed ID: 26907775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Toolkit of CRISPR-Based Genome Editing Systems in Drosophila.
    Xu J; Ren X; Sun J; Wang X; Qiao HH; Xu BW; Liu LP; Ni JQ
    J Genet Genomics; 2015 Apr; 42(4):141-9. PubMed ID: 25953352
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CRISPR-Cas9 Targeting of PCSK9 in Human Hepatocytes In Vivo-Brief Report.
    Wang X; Raghavan A; Chen T; Qiao L; Zhang Y; Ding Q; Musunuru K
    Arterioscler Thromb Vasc Biol; 2016 May; 36(5):783-6. PubMed ID: 26941020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CRISPR/Cas9 Engineering of Adult Mouse Liver Demonstrates That the Dnajb1-Prkaca Gene Fusion Is Sufficient to Induce Tumors Resembling Fibrolamellar Hepatocellular Carcinoma.
    Engelholm LH; Riaz A; Serra D; Dagnæs-Hansen F; Johansen JV; Santoni-Rugiu E; Hansen SH; Niola F; Frödin M
    Gastroenterology; 2017 Dec; 153(6):1662-1673.e10. PubMed ID: 28923495
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of microsatellite instability in CRISPR/Cas9 editing mice.
    Huo X; Du Y; Lu J; Guo M; Li Z; Zhang S; Li X; Chen Z; Du X
    Mutat Res; 2017 Mar; 797-799():1-6. PubMed ID: 28284774
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retroviral Vectors for Cancer Gene Therapy.
    Schambach A; Morgan M
    Recent Results Cancer Res; 2016; 209():17-35. PubMed ID: 28101685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CRISPR/Cas9-Based Genome Editing for Disease Modeling and Therapy: Challenges and Opportunities for Nonviral Delivery.
    Wang HX; Li M; Lee CM; Chakraborty S; Kim HW; Bao G; Leong KW
    Chem Rev; 2017 Aug; 117(15):9874-9906. PubMed ID: 28640612
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Smart Programmable CRISPR Technology: A Next Generation Genome Editing Tool for Investigators.
    Chakraborty C; Teoh SL; Das S
    Curr Drug Targets; 2017; 18(14):1653-1663. PubMed ID: 27231109
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene Editing With CRISPR/Cas9 RNA-Directed Nuclease.
    Doetschman T; Georgieva T
    Circ Res; 2017 Mar; 120(5):876-894. PubMed ID: 28254804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CRISPR-Cas9, A Promising Therapeutic Tool for Cancer Therapy: A Review.
    Akram F; Ikram Ul Haq ; Ahmed Z; Khan H; Ali MS
    Protein Pept Lett; 2020; 27(10):931-944. PubMed ID: 32264803
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The potential application and challenge of powerful CRISPR/Cas9 system in cardiovascular research.
    Li Y; Song YH; Liu B; Yu XY
    Int J Cardiol; 2017 Jan; 227():191-193. PubMed ID: 27847153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CRISPR-Cas9 Genome Editing for Treatment of Atherogenic Dyslipidemia.
    Chadwick AC; Musunuru K
    Arterioscler Thromb Vasc Biol; 2018 Jan; 38(1):12-18. PubMed ID: 28838920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic applications of CRISPR RNA-guided genome editing.
    Koo T; Kim JS
    Brief Funct Genomics; 2017 Jan; 16(1):38-45. PubMed ID: 27562951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.